Status:
COMPLETED
Study to Investigate Safety and Tolerability of a Single Dose of AZD6482
Lead Sponsor:
AstraZeneca
Conditions:
Antiplatelet Effect
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
AZD6482 is a new drug substance aiming to prevent blood clots which may arise in atherosclerotic blood vessels and cause myocardial infarction or stroke. This is the first study with AZD6482 in humans...
Eligibility Criteria
Inclusion
- BMI between 19.0 and 30.0 kg/m2, inclusive and body weight between 50.0 and 100.0 kg, inclusive
- Provision of written informed consent
Exclusion
- Personal or family history of bleeding disorders, or reasonable suspicion of vascular malformations, including aneurysms.
- Acute illness, surgical procedure or trauma from 2 weeks before pre-entry visit until administration of investigational product or clinically significant abnormalities in clinical chemistry, haematology, faeces, urinalysis or supine BP or pulse
- Known impaired glucose intolerance or known or suspected Gilbert´s syndrome
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT00688714
Start Date
January 1 2008
End Date
May 1 2008
Last Update
June 3 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.